139 related articles for article (PubMed ID: 19411029)
1. The study of influence factors on (131)I treatment of differentiated thyroid carcinoma with lymph node metastases.
Ye ZY; Wang H; Fu HL; Li JN; Zou RJ; Gu ZH; Wu JC
Clin Imaging; 2009; 33(3):221-5. PubMed ID: 19411029
[TBL] [Abstract][Full Text] [Related]
2. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT.
Kaneko K; Abe K; Baba S; Isoda T; Yabuuchi H; Sasaki M; Hatakenaka M; Honda H
Clin Nucl Med; 2010 Jan; 35(1):6-11. PubMed ID: 20026964
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
6. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
[TBL] [Abstract][Full Text] [Related]
7. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
[TBL] [Abstract][Full Text] [Related]
9. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area.
Mishra A; Mishra SK; Agarwal A; Das BK; Agarwal G; Gambhir S
World J Surg; 2002 Feb; 26(2):153-7. PubMed ID: 11865341
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
11. Does the presence of regional lymph node metastases have any impact on the complete remission rate in patients with distant metastases of papillary thyroid carcinoma (PTC), treated by radioiodine therapy?
Trybek T; Kowalska A
Endokrynol Pol; 2010; 61(5):443-5. PubMed ID: 21049455
[TBL] [Abstract][Full Text] [Related]
12. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid carcinoma referred for radioiodine therapy.
Al-Balawi IA; Meir HM; Yousef MK; Nayel HA; Al-Mobarak MF
Saudi Med J; 2001 Jun; 22(6):497-503. PubMed ID: 11426239
[TBL] [Abstract][Full Text] [Related]
14. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A
Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861
[TBL] [Abstract][Full Text] [Related]
15. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
16. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study.
Ilhan H; Mustafa M; Bartenstein P; Kuwert T; Schmidt D
Nuklearmedizin; 2016 Dec; 55(6):221-227. PubMed ID: 27588323
[TBL] [Abstract][Full Text] [Related]
17. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
18. Parameters Influencing Curative Effect of 131I Therapy on Pediatric Differentiated Thyroid Carcinoma: A Retrospective Study.
Xu L; Liu Q; Liu Y; Pang H
Med Sci Monit; 2016 Aug; 22():3079-85. PubMed ID: 27576533
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131: An Effective Method for Treating Lymph Node Metastases of Differentiated Thyroid Cancer.
He Y; Pan MZ; Huang JM; Xie P; Zhang F; Wei LG
Med Sci Monit; 2016 Dec; 22():4924-4928. PubMed ID: 27974741
[TBL] [Abstract][Full Text] [Related]
20. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
